Personal profile
Biography
Jim Read has more than a decade of experience managing clinical trials data, computer system administration and developing software. Currently they leads a team of six data management professionals within the Global Health Trials Unit at Liverpool School of Tropical Medicine (LSTM). The team supports LSTM trial operations around the world with database development, data management, dashboarding, reports and bespoke software solutions. This allows collaborating teams to maximise the quality of data collection and oversight of endpoints. Jim’s background in full stack software development, big data utilisation, and early adopter innovations equips them to push new concepts and develop systems to maximise efficiency. Since joining LSTM in January 2020, Jim has implemented data warehousing facilities, centralised reporting tools, developed document management software, and implemented a suite of Standard Operating Procedure documents that drive operations. As a member of the Research Integrity Work Group, they support conducting research with best practices and is connected through Research Integrity colleagues to the research culture across the university. Prior to LSTM they worked for the Cancer Trials Unit at the University of Liverpool and has a breadth of experience operating MHRA regulated UK clinical studies and producing systems that support full audits (without major findings).
Research interests
Jim supports the research interests of students, researchers and teachers across LSTM. Their team develops new systems and methodologies for working with and tracking operations using data to provide real time support for data collectors. In combination with the scientific computing team, they are looking to develop in-house artificial intelligence solutions to further enhance data quality and review.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
-
SDG 3 Good Health and Well-being
Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
-
Infant HIV transmission despite maternal viral suppression: a case of post-weaning seroconversion
Nakalema, S., Namuddu, D., Kyohairwe, I., Nakatudde, I., Malaba, T., Myer, L., Colbers, A., Reynolds, H., Read, J., Lamorde, M., Khoo, S. & Waitt, C., 4 Mar 2026, In: Journal of Antimicrobial Chemotherapy. 81, 4, dkag072.Research output: Contribution to journal › Article › peer-review
Open AccessFile -
Abstracts of the 26th International Workshop on Clinical Pharmacology of HIV, Hepatitis and other Antiviral Drugs 2025, 3-4 September 2025, Amsterdam, the Netherlands
Dickinson, L., Singh, Y., Semakula, J., Chodacki, P., Kassim, S., Namuddu, D., Sihlangu, M., Read, L., Else, L., Reynolds, H., Thompson, B., Monk, R., Lawson, A., Ayre, C., Read, J., Wang, D., Waitt, C., Orrell, C. & Khoo, S., 1 Sept 2025, In: British Journal of Clinical Pharmacology. 91, p. 11 1 p.Research output: Contribution to journal › Meeting Abstract
Open Access -
The Effects on the Growth of HIV-exposed Uninfected Infants of Initiating Dolutegravir-based Versus Efavirenz-based cART in Late Pregnancy (DolPHIN-2)
Hagens, L., Bevers, L. A. H., Malaba, T. R., Nassiwa, S. C., Mrubata, M., Theunissen, H., Reynolds, H., He, N., Read, J., Burger, D. M., Lamorde, M., Myer, L., Wang, D., Khoo, S., Waitt, C. & Colbers, A., 18 Jul 2025, (E-pub ahead of print) In: Pediatric Infectious Disease Journal. 44, 11, p. 1066-1071 6 p.Research output: Contribution to journal › Article › peer-review
Open AccessFile -
Cost-Effectiveness of Dolutegravir Compared With Efavirenz for Prevention of Perinatal Transmission in Women Presenting With HIV in Late Pregnancy in Uganda.
Nuwamanya, E., Nassiwa, S. C., Kuznik, A., Waitt, C., Malaba, T., Myer, L., Colbers, A., Read, J., Wang, D. & Lamorde, M., 1 Nov 2024, In: Value in Health Regional Issues. 44, p. e101017 101017.Research output: Contribution to journal › Article › peer-review
Open AccessFile3 Citations (Scopus) -
72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study.
Malaba, T. R., Nakatudde, I., Kintu, K., Colbers, A., Chen, T., Reynolds, H., Read, L., Read, J., Stemmet, L. A., Mrubata, M., Byrne, K., Seden, K., Twimukye, A., Theunissen, H., Hodel, E. M., Chiong, J., Hu, N. C., Burger, D., Wang, D. & Byamugisha, J. & 30 others, , 1 Aug 2022, In: The Lancet HIV. 9, 8, p. e534-e543Research output: Contribution to journal › Article › peer-review
Open AccessFile50 Citations (Scopus)